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ABSTRACT 
 
Apoptosis, a form of programmed cell death, is critical to homoeostasis, normal 
development, and physiology. Dysregulation of apoptosis can lead to the accumulation 
of unwanted cells, such as occurs in cancer, and the removal of needed cells or 
disorders of normal tissues, such as heart, neurodegenerative, and autoimmune 
diseases. Noninvasive detection of apoptosis may play an important role in the 
evaluation of disease states and response to therapeutic intervention for a variety of 
diseases. It is desirable to have an imaging method to accurately detect and monitor 
this process in patients. In this study, we developed annexin A5-conjugated polymeric 
micellar nanoparticles dual-labeled with a near-infrared fluorescence fluorophores (Cy7) 
and a radioisotope (111In), named as 111In-labeled annexin A5-CCPM. In vitro studies 
demonstrated that annexin A5-CCPM could strongly and specifically bind to apoptotic 
cells. In vivo studies showed that apoptotic tissues could be clearly visualized by both 
single photon emission computed tomography (SPECT) and fluorescence molecular 
tomography (FMT) after intravenous injection of 111In-labeled Annexin A5-CCPM in 6 
different apoptosis models. In contrast, there was little signal in respective healthy 
tissues. All the biodistribution data confirmed imaging results. Moreover, histological 
analysis revealed that radioactivity count correlated with fluorescence signal from the 
nanoparticles, and both signals co-localized with the region of apoptosis.  In sum, 111In-
labeled annexin A5-CCPM allowed visualization of apoptosis by both nuclear and 
optical imaging techniques. The complementary information acquired with multiple 
imaging techniques should be advantageous in improving diagnostics and management 
of patients. 
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INTRODUCTION 
 
1. Apoptosis 
1.1 Mechanism of Apoptosis 
Apoptosis, a form of programmed cell death, is defined as a regulated 
energy-dependent process, characterized by specific morphological and 
biochemical features in which caspases play a central role. Apoptosis is 
considered a critical component of multiple biological processes, which include 
normal cell turnover, embryonic development, hormone-dependent atrophy, 
proper development and functioning of the immune system, and chemical-
induced cell death (1-9). The mechanisms of apoptosis are highly complex, 
which involve a cascade of molecular events. To date, it is well known that there 
are three main apoptotic pathways, including the extrinsic pathway, the intrinsic 
pathway, and perforin/granzyme pathway (Fig. 1). These three pathways 
converge on the same terminal and execution pathway, which is initiated by the 
cleavage of caspase-3 and leads to DNA fragmentation, proteins cross-linking, 
proteins degradation, formation of apoptotic bodies, expression of ligands for 
phagocytosis and finally uptake by phagocytic cells (1-9).  
In general, a variety of injurious stimuli such as radiation, heat, hypoxia 
and drugs can induce apoptosis. In this study, to mimic massive apoptosis that 
occurs in some tissues, we use anticancer drugs (e.g.  cyclophosphamide, 
etoposide, poly(L-glutamic acid)-paclitaxel and cetuximab) to induce tumor 
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Figure 1. Schematic representation of apoptotic events. The three main 
pathways of apoptosis are extrinsic and intrinsic as well as a perforin/granzyme 
pathway. Each requires specific triggering signals to begin an energy dependent 
cascade of molecular events. Each pathway activates its own initiator caspase 
(8, 9, 10) which in turn will activate the executioner caspase-3. However, 
granzyme A works in a caspase-independent fashion. The execution pathway 
results in characteristic cytomorphological features including cell shrinkage, 
chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies 
and finally phagocytosis of the apoptotic bodies by adjacent parenchymal cells, 
neoplastic cells or macrophages. (Reprinted with permission of (9)) 
 
 
 
apoptosis (10-13), anti-Fas antibody to induce hepatic apoptosis (14), and 
turpentine to induce muscle inflammation (15). Cyclophosphamide is widely 
used to treat several types of cancer, such as lymphoma, leukemia, breast 
cancer, and ovarian cancer (16-18). Anti-Fas antibody, which binds to hepatic 
Fas receptors, can be used to induce massive apoptosis of hepatocytes in mice 
within a few hours, mimicking fulminant hepatitis (19). Turpentine can be used 
as a stimulus to trigger a series of inflammation reactions after intramuscular 
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injection, such as migration of granulocytes to the injured tissues, and clearance 
of apoptotic granulocytes through PS-specific recognition by monocytes (15). 
 
1.2 Importance of Imaging Apoptosis 
Dysregulation of apoptosis can lead to a number of diseases. Too little 
apoptosis can result in accumulation of unwanted cells, such as occurs in 
cancer, rheumatoid arthritis, systemic lupus erythematosus (SLE), and 
autoimmune lymphoproliferative syndrome (ALPS). In contrast, too much 
apoptosis can lead to the removal of needed cells or disorders of normal tissues, 
such as acute myocardial infarction (AMI), chronic heart failure, allograft 
rejection, stroke, inflammation, autoimmune diseases (AIDS), and 
neurodegenerative diseases (e.g. Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease, and Amyotrophic Lateral Sclerosis) (1, 20-28). 
Additionally, the detrimental or beneficial effect of many drugs is attributed to 
their action on the apoptotic process (20, 29-31). For example, chemotherapy 
and radiotherapy are widely used in clinic to induce tumor apoptosis. Since 
apoptosis is involved in a number of diseases and therapeutic procedures, it is 
necessary to in vivo monitor the rate and extent at which apoptosis occurs 
(Table 1).  The purpose of this project is to develop a non-invasive imaging 
tracer for detection of apoptosis, which may provide relevant information on 
disease activity and therapeutic efficacy. 
 
 
~ 4 ~ 
 
 
 
Table 1. Medical field for application of apoptosis imaging. Abbreviations: AMI, 
Acute myocardial infarction; ARVD, arrhythmogenic right ventricle dysplasia; 
CAD, coronary artery disease; CHF, congestive heart failure; MODS, multiple 
organ dysfunction syndrome; SLE, systemic lupus erythematosus. (Reprinted 
with permission of (20)) 
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1.3 Assays for Apoptosis 
During apoptosis, cells exhibit several biochemical modifications, such as 
protein cleavage, protein cross-linking, morphological change, DNA 
fragmentation, and expression of cell surface markers, which together lead to 
the distinctive structural pathology described previously (3, 9). Thus, a variety of 
apoptosis assays are devised to detect and count apoptotic cells. Based on 
methodology, current apoptosis assays can be classified into six major groups 
and a subset of specific assays in each group is listed in Table 2. (Reprinted 
with the permission of (9)) 
 
 
 
 Methodology  Techniques 
Cytomorphological alterations Hematoxylin and eosin staining (H&E); 
Transmission electron microscopy (TEM). 
DNA fragmentation DNA laddering; 
Terminal dUTP nick end labeling (TUNEL). 
Detection of caspases, cleaved substrates, 
regulators and inhibitors 
Immunostaining (anti-caspase antibody); 
PCR microassay. 
Detection of apoptosis in whole mounts Staining (acridine orange, Nile blue sulfate, 
and neutral red). 
Mitochondrial assays Laser scanning confocal microscopy (LSCM). 
Membrane alterations Fluorophore/radio-labeled annexin A5 
derivatives. 
 
Table 2. Assays for detection of apoptosis. 
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Although there are a variety of assays available, each assay has 
advantages and disadvantages which may make it appropriate for one 
application but inappropriate for another (32, 33). ① .Cytomorphological 
Changes: Based on the morphological changes during apoptosis, apoptotic cells 
can be detected using transmission electron microscopy (TEM), or light 
microscopy incorporated with hematoxylin and eosin (H&E) staining. TEM is 
used as a golden standard to confirm apoptosis, because of certain 
ultrastructural morphological characteristics (9, 34), However, because the 
morphological changes generally occur in the later phase of apoptosis, apoptotic 
cells in the early phase will not be detected with these methods. Additionally, 
these methods, particularly TEM, only allow visualizing a small region at a time. 
②.DNA Fragmentation: DNA laddering technique and terminal dUTP nick end-
labeling (TUNEL) can be used to assay the endonuclease cleavage products of 
apoptosis (35). Owing to commercial kits from various companies, these assays 
are fast and easily accessible. The disadvantage is that these methods are only 
suitable for detection of apoptosis in the later phase. ③.Detection of caspases, 
cleaved substrates, regulators and inhibitors: The activation of certain proteins in 
apoptotic process can be detected using western blot, immunohistochemistry, or 
immunoprecipitation (36, 37). For example, anti-caspase 3 antibody was used in 
this study to locate apoptotic area in tumor section. This assay allows for fast 
and consistent quantification of apoptotic cells. However, because these 
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proteins such as caspases are involved in several different cell activities and are 
not specific to apoptosis, their activation doesn’t necessarily indicate occurance 
of apoptosis. ④.Detection of Apoptosis in Whole Mounts: Apoptosis also can be 
visualized in whole mounts using some dyes, such as acridine orange (AO), 
neutral red (NR), and Nile blue sulfate (NBS) (38). This is because these 
acidophilic dyes are easily concentrated in the areas of high lysosomal and 
phagocytotic activity. Although this assay is fast and inexpensive, it still has 
certain disadvantages. For example, AO is toxic and quenches rapidly whereas 
NBS and NR are unstable and hardly penetrate thick tissues. ⑤.Mitochondrial 
Assay: some mitochondrial parameters can be monitored for detection of 
apoptosis, such as mitochondrial permeability transition (MPT), Ca2+ fluxes, 
reactive oxygen species, depolarization of the inner mitochondrial membrane, 
and mitochondrial redox status (39, 40). However, these mitochondrial events 
also occur during necrosis and other cell activities. Therefore, it is necessary to 
use other apoptosis assays to confirm the result. ⑥.Membranes Alterations: Cell 
plasma membranes maintain an asymmetric distribution of lipid molecules in the 
bilayer. Phosphatidylserine (PS), a component of cell membrane phospholipids, 
localizes in the inner plasma membrane. The intracellular localization of PS is 
maintained by an ATP-dependent aminophospholipid translocase that shuttles 
PS from the outer to the inner leaflet in viable cells. In the early stage of 
apoptosis, cellular mechanisms which maintain PS asymmetry, become 
inactivated and lead to externalization of PS on the outer surface of membrane 
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(Fig. 2) (41-43). The externalized PS on the outer surface of apoptotic cells is 
considered a “eat-me” signal for phagocytosis, potentially allowing for detection 
of apoptosis via Fluorophore/radio-labeled annexin A5 (44). The main 
advantages of this assay are sensitivity (can detect a single apoptotic cell) and 
ability to detect apoptosis in the early phase. In addition, this assay is fast, 
inexpensive and easy-to-use. Thus, we took advantage of this methodology for 
imaging apoptosis in this study. (Reprinted with the permission of (9)) 
 
 
 
Figure 2. Maintaining normal membrane polarity by translocase and floppase 
activity (left). Diagram of the cell membrane with phospholipid head groups 
(circular structures) and tails (interior of the lipid bilayer), with two enzyme 
channels: (1) floppase pumping sphingomyelin, phosphatidylethanolamine and 
phosphatidylcholine to the exterior leaflet; and (2) translocase pumping 
phosphatidylserine to the inner leaflet. Expression of phosphatidylserine due to 
scramblase activation (right). Diagram of a portion of the cell membrane in a cell 
undergoing apoptosis. The enzyme scramblase is activated, resulting in the 
active transfer of phosphatidylserine from the inner to the outer leaflet of the cell 
membrane in parallel with the transfer of the other lipids to the inner leaflet. 
These changes occur as the cell membrane forms a bleb, which will break off to 
form an apoptotic body. (Reprinted with permission of (43)) 
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2. Annexin A5 
2.1 Introduction of Annexin Family and Annexin A5 
Annexins are well-known multigene family of calcium-regulated and 
phospholipid-binding proteins expressed in most eukaryotic cells. Structurally, all 
annexins share a unique core domain consist of four similar repeats, each 
approximately 70 amino acids long. Despite their structural similarities, annexins 
have diverse biological functions in biological activities, such as apoptosis, cell 
division, calcium signaling, vesicle trafficking, regulation of membrane 
organization, and regulation of growth. In the past decades, 12 annexin 
members common to vertebrates were observed and classified in annexin A 
family (annexins A1-A11 and A13) [4]. Annexins outside vertebrates are 
classified into families B (in invertebrates), C (in fungi), D (in plants), and E (in 
protists) (45-50). 
Annexin A5 (molecular weight 36 KDa), also known as annexin V, is an 
endogenous human protein that consists of 319 amino acids (Fig. 3), which is 
widely expressed in eukaryotic organisms and mainly found intracellularly on the 
cytosolic side of plasma membranes (51-55). This protein is also expressed in 
various cell types, such as erythrocytes, glial cells, vascular endothelium, 
thrombocytes, hepatocytes, bronchi, astrocytes, lymphocytes, chondrocytes, 
oligodendrocytes, Schwann cells, osteoblasts, skeletal muscles, and 
cardiomyocytes (56-62). In human, there is very low concentration (1–6 ng/ml) of 
annexin A5 circulating in the blood pool (20). To date, several biological 
properties of annexin A5 have been reported, including regulation of 
~ 10 ~ 
 
phospholipase A2 (63, 64), Ca2+-channel activities (65, 66), inhibition of 
phagocytosis of apoptotic cells by macrophages (67-69) and immune modulation 
(70, 71). 
 
 
 
Figure 3. X-ray analysis revealed the tertiary structure of annexin A5, as 
depicted here. The protein consists of 319 amino acids. Molecule is arranged in 
planar cyclic structure of 4 domains, which are indicated by different colors in 
structure. Also shown are Ca2_ ions (green spheres). (Reprinted with 
permission of (51)) 
 
 
 
Annexin A5 is known to specifically and strongly bind to 
Phosphatidylserine on the surface of apoptotic cells with nanomolar affinity (Kd= 
0.5 – 7 nM) (Fig. 4) (20, 52, 53). Recently, it was reported that annexin A5 not 
only binds to PS but also forms a two-dimensional network on the surface that 
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causes its internalization (72). With the onset of apoptosis, the number of 
annexin A5-binding sites per cell can increase 100- to 1,000-fold, reaching 
values of about 4 million in some cell lines (73, 74). Considering annexin A5 a 
promising ligand which binds to apoptotic cells, we introduced it in our nano-
scale imaging system in this study for targeting.  
 
 
Figure 4. Schematic representation of the loss of membrane lipid asymmetry 
during apoptosis. Vital cells maintain a strictly asymmetric lipid bilayer 
composition, with PS residues (red circles) facing the cytosol. During apoptosis 
these PS molecules become exposed at the outer membrane leaflet Hapten-
labeled annexin V can bind with high affinity to the exposed PS in the presence 
of millimolar Ca2+-concentration. (Reprinted with permission of (52)) 
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2.2 Annexin A5 Derivatives for Imaging Apoptosis  
Van den Eijnde and co-workers were the first to demonstrate that annexin 
A5 can detect apoptosis in vivo (75). Today, annexin A5 is the most widely used 
in the visualization of apoptosis. In recent years, a variety of annexin A5 
derivatives have been developed for the detection of apoptosis with different 
imaging modalities, including fluorescence (76, 77), positron emission 
tomography (PET) (78-81), single photon emission computed tomography 
(SPECT) (14, 15, 23, 82-87), and magnetic resonance imaging (MRI) (88, 89).  
 
 
Table 3. List of clinical trials (phase I/III). Abbreviations: (A)MI, (Acute) 
myocardial infarction; IP, ischaemic preconditioning; MRI, magnetic resonance 
imaging; NSCLC, non-small cell lung cancer. (Reprinted with permission of (20)) 
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Among these derivatives, the radiolabeled annexin A5 analogues are the 
most advanced in human clinical trials (Table 3) (14, 15, 23, 82-87). In the past 
decades, a number of studies were conducted to investigate annexin A5 
derivatives labeled with different radioisotopes (e.g. 99mTc, 94mTc, 123I, 124I, 125I, 
18F, 111In, 11C, 64Cu, 67Ga and 68Ga) (20, 90). Due to the substantial advantages 
of 99mTc over many other radionuclides, 99mTc-labeled annexin A5 is the most 
extensively investigated and broadly used. The radioisotope 99mTc is 
inexpensive, easily available, and has short half-life (~6 h) and optimal imaging 
properties for SPECT. Various radiochemical techniques of 99mTc-labeling were 
used, such as indirect labeling through chelators and co-ligands (e.g. N2S2, 
HYNIC, EC, MAG3, BTAP, EDDA, SDH, iminothiolane, tricarbonyl) or direct 
labeling with annexin A5 mutants (20). The improvement of radiochemistry leads 
to better radiochemical purity, efficiency, stability, and in vivo imaging properties 
(e.g. biodistribution and pharmacokinetics) (91-98). Currently, the radiolabeling 
procedure was further improved into a kit formulation which only requires 15 min 
for reaction. Moreover, the specific activity is very high and reaches 198–265 
GBq/μmol, making 99mTc-labeled annexin A5 much more useful for in vivo 
imaging applications (20).  
Annexin A5 also can be conjugated with fluorochromes for optical 
imaging of apoptosis. Koopman et al. first reported a flow cytometric method for 
detection of PS expression on apoptotic B cells by fluorochrome-labeled annexin 
A5 (99). To date, this kind of fluorochrome-labeled annexin A5 incorporated with 
fluorescence-activated cell sorting (FACS) and flow cytometry (100, 101) are 
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now routinely used to identify apoptotic cells. It was also reported that annexin 
A5 labeled with near-infrared fluorescence dye (Cy5.5) could be applied for 
imaging tumor apoptosis in vivo (102). This optical approach could overcome 
some limitations of radioligands, such as radiation exposure, high cost, and a 
limited time window for consecutive monitoring apoptosis due to a short half-life. 
Moreover, optical imaging technique allows monitoring ongoing apoptosis in real 
time. However, owing to limited tissue penetration depth of light, optical imaging 
is mostly used for in vitro detection of apoptosis, or combined with other imaging 
modalities to provide complimentary information.  
In effort to develop a non-invasive imaging modality for in vivo detection 
of apoptosis, annexin A5 recently was conjugated with some MRI contrast 
agents, such as super paramagnetic iron oxide nanoparticles (SPIO) and cross-
linked iron oxide nanoparticles (CLIO) (88, 103). Both contrast agents showed a 
considerable potential for successful detection of apoptosis by MRI. 
In this project, with respect to en-vogue concept of multimodal imaging, 
annexin A5 was conjugated to nanoparticles dual-labeled with radioisotopes and 
fluorochromes. This design enabled its use for both nuclear and optical imaging. 
 
3. Multimodal Imaging 
3.1 Importance of Multimodal Imaging 
Imaging is a crucial part in the process of diagnosis and treatment, with 
which differential diagnosis, lesion detection, evaluation of disease severity and 
monitoring of therapeutic efficacy are performed. At present, diverse imaging 
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techniques are available, including optical imaging, positron emission 
tomography (PET), single photon emission computed tomography (SPECT), 
computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound 
(104). However, none of the current imaging methods used in humans provides 
comprehensive medical imaging. Combinations of imaging modalities that 
integrate the strengths of two modalities, and at the same time eliminate one or 
more weaknesses of an individual modality, thus enhance the imaging accuracy 
and provide complimentary information for improving diagnostics and 
management of patients (Table 4) (105-110). A common practice today is to 
combine techniques with high detection sensitivity such as PET and SPECT with 
those with high spatial resolution such as CT, MRI, and ultrasound. For 
example, the first fused PET/CT instrument was developed in 1998 by 
Townsend and was available commercially in 2001. Its success was such that 
by 2003 fused PET/CT instruments were available from all of the major clinical 
instrument manufacturers, such as GE, Siemens, and Philips. Over the ensuing 
years, PET/CT sales increased with such vigor. Today, there are virtually no 
sales of standalone PET instruments and all PET sales are as part of 
multimodality systems (109).  
Optical imaging methods are the most widely used in preclinical 
molecular imaging, whereas nuclear imaging is the most effective clinical 
imaging modality. No single imaging modality is perfect. To harness the 
strengths of these two different imaging methods, we combined SPECT/CT and 
fluorescent optical imaging for detection of apoptosis in this study. Because the 
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multimodality imaging techniques can provide complimentary information for 
diagnosis, 1 + 1 can add up to more than 2 when it comes to multimodality 
imaging systems.  
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3.2 Nuclear Imaging 
The radioactive tracer was first introduced in the living system by de 
Hevesy and Paneth at 1923 to study metabolism dates. Today, nuclear imaging 
techniques such as PET and SPECT, have been an essential part of the 
treatment scheme of patients with various diseases. It can be applied to 
investigate biological activities (e.g. metabolic rate, transport rate, and binding 
capacity) as well as to detect the utilization of an endogenous analogue (e.g. ion, 
hormone, and substrate) or the expression of its corresponding biochemical 
counterpart (e.g. enzyme, receptor, and transporter) (111-113). Most of radio-
tracers used in nuclear imaging are based on metabolism, biochemistry and 
physiology underlying the process they image. Nuclear imaging can offer high 
sensitivity at deep tissue sites and capability of quantification. It is by far the 
most effective clinical molecular imaging modality. Owing to the weak spatial 
resolution of nuclear imaging, knowing the existence of the abnormality but not 
its precise location may decrease their impact on the diagnosis of diseases. 
Therefore, multimodal imaging devices such as PET/CT, SPECT/CT, and 
PET/MRI, are in development at present, which can produce a final 3-
dimensional image of biological and anatomical information fused together.  
Since no imaging technique is perfect, nuclear imaging also has certain 
disadvantages. For example, nuclear imaging may suffer from low photon 
counts requiring long scan times as well as from a finite half-life and radiation 
dosage preventing longitudinal imaging in patients (114, 115). Moreover, nuclear 
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imaging are expensive and do not provide sufficient resolution to image detail in 
real time. An alternative is optical imaging. 
 
3.3 Optical Imaging 
Optical imaging such as fluorescence and bioluminescence, is an 
inexpensive, easily accessible, and non-radiation technique that can be used to 
visualize biologic systems at whole-body level as well as at the molecular and 
cellular level (116-121). Optical imaging can be carried out noninvasively in real 
time, yielding high spatial resolution. Today, optical imaging has become an 
active and promising area for in vivo molecular imaging, which makes a 
substantial impact on basic science and translational medical research (122, 
123). Furthermore, this technique has already entered initial clinical testing in 
several areas. For example, diffuse optical spectroscopy of hemoglobin and 
deoxyhemoglobin in breast tumors shows promise as a biomarker for effective 
neoadjuvant chemotherapy in cancer patients (123, 124). 
In vivo optical imaging is based on detection of light passing through 
tissues. Thick and opaque tissues can absorb photons and generate strong 
autofluorescence, all of which will obscure signal acquisition. However, these 
obstacles are less problematic in the near-infrared (NIR) region (650-900nm). 
Light in the NIR wavelength region can travel several centimeters through living 
tissue. Hemoglobin (the principal absorber of visible light) and water and lipids 
(the principal absorbers of infrared light) have their lowest absorption coefficient 
in the NIR region. Moreover, most tissues generate little fluorescence in the NIR 
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region, which allows improving ratios of target to background in image (125-129).  
Recently, 3-dimensional imaging and analysis techniques such as fluorescence 
molecular tomography (FMT) have been developed to investigate deep tissues 
(e.g. spleen, lung, and liver). FMT can provide 3D volumetric imaging, true 
quantification independent of depth, tissue optical properties and heterogeneity, 
and augmentation of the contrast by reducing the autofluorescence (125, 127). 
This technique will soon be transferred to the clinic for imaging deep events. In 
this project, we labeled our imaging tracer with NIR fluorophores (Cyanine 7) for 
optical imaging. Cyanine 7, also named as Cy7, is a NIR fluorescent dye that 
belongs to the Cyanine family of synthetic polymethine dyes. It is water-soluble, 
and has an absorbance maximum of 747 nm and an emission maximum of 776 
nm. 
 
4. Nanoparticles 
Although our radiotracer (111Indium) and NIR fluorophore (Cyanine 7) 
possess excellent imaging properties, neither is tumor specific. To address this 
problem, a targeting moiety like nanoparticles, was introduced in this study to 
specifically deliver a dual-labeled imaging agent to diseased sites. Nanoparticles 
are artificially created materials with dimensions typically smaller than 200 nm. 
Because of their unique sizes, nanoparticles fill a critical position between the 
macroscopic world and molecular-level detail and can be designed to offer 
unique advantages over macroscopic materials and molecular systems (130-
134). These technological innovations, referred to as nanomedicines by the 
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National Institutes of Health, have a potential to turn molecular discoveries 
arising from proteomics and genomics into broad benefit for patients. The 
development of nanomedicines is beginning to change the foundations of 
disease diagnosis, treatment, and prevention (130-134). In the past decades, a 
great number of nanoparticles have been developed and some of them showed 
a great potential. For example, Abraxane, a nanoparticle version of paclitaxel 
bound to albumin, has good water solubility. It has been shown to be much more 
effective than previous formulations of paclitaxel, and has already been 
approved by the FDA (135, 136).  
Nanoparticles have a unique advantage for molecular imaging in which 
many functions can be added to the surface and interior of the particle. For 
example, multiple diagnostic (e.g., radioisotopic, optical, or magnetic) agents, 
targeting ligands, and polyethylene glycol can be attached to nanoparticles, to 
provide imaging signal, targeting effect, and alteration of pharmacokinetics. 
Recent advances have led to a number of targeting multifunctional nanoparticles 
for molecular imaging, drug delivery, and other therapeutic procedures (e.g. 
radiotherapy, or phototherapy) (137-142). Moreover, owing to their large surface 
area-to-volume ratio, nanoparticles are able to deliver large numbers of imaging 
agents per each targeted molecular recognition event to improve sensitivity of 
imaging, as well as several different types of imaging agents to perform 
multimodality imaging. To sum, with an increasing number of nanoparticle 
techiques funded by government, submitted for patents and under review by the 
FDA, the outlook for nanoparticle systems in medical application is promising. 
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5. Significance 
Apoptosis is critical to homoeostasis, normal development, and 
physiology. Abnormal apoptosis is associated with a number of diseases and 
therapeutic procedures. It is desirable to have an imaging method to accurately 
detect and monitor this process in patients. Therefore, the major goal in this 
study is to develop a novel targeting nanoparticle dual-labeled by NIRF optical 
dyes and nuclear isotopes for early detection and monitoring of apoptosis. The 
novel diagnostic approach potentially permits whole-body visualization to locate 
apoptosis by nuclear imaging (e.g. PET or SPECT), followed by fluorescence 
imaging guided biopsies to define precisely extent and region of local apoptosis. 
According to complimentary diagnostic information, clinicians can accurately 
evaluate disease activities and therapeutic outcome. Accurate and rapid 
feedback on treatment response will facilitate next phages of therapy. I 
anticipate that success of this project will lead to the development of novel 
approaches for diagnosis of apoptosis by bringing together advances in 
nanotechnology, apoptosis research, and imaging science. Translation of this 
discovery from basic science to practical clinic will potentially improve the 
efficacy of detection of apoptosis and the management of patients after various 
therapeutic interventions. 
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MATERIALS AND METHODS 
 
1. Reagents 
Common reagents were purchased from Sigma-Aldrich (St. Louis, MO) or 
Acros (Geel, Belgium) and used as received unless otherwise specified. Annexin 
A5 was obtained from Theseus Imaging Corp. (Cambridge, MA). CCPM 
nanoparticle was a kind gift of Carestream Health, Inc. (Rochster, NY). p-
Isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (DTPA-Bz-NCS) was 
purchased from Macrocyclics (Dallas, TX). Indium-111 chloride (111InCl3) was 
obtained from Perkin Elmer (Waltham, MA). 
 
2. Synthesis of CCPM Nanoparticles.  
CCPM nanoparticles were a kind gift of Carestream Health, Inc. 
(Rochester, NY). The reaction scheme for synthesis of CCPM nanoparticles is 
shown in Figure 5. The detailed procedure for synthesis of CCPM nanoparticles 
was described below. (Reprinted with permission of (143)) 
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Figure 5. Synthesis of PPEGMA-b-PESPMA block copolymer and schematic 
illustration of the preparation of amine-terminated, core-crosslinked polymeric 
micelles containing NIRF dyes. (Reprinted with permission of (143)) 
 
 
 
2.1 Analytical Methods 
1H and 13C NMR spectra were recorded on a Varian XL-300 spectrometer 
(Varian, Inc., Palo Alto, CA) operating at 300 MHz with tetramethyl silane (TMS) 
as an internal standard. Molecular weights were determined with gel permeation 
chromatography (GPC) using poly(methyl methacrylate) with narrow molecular 
weight distribution as standards. The samples were separated using two 7.5 × 
300 mm PLgel mixed-C columns (Polymer Laboratories, Amherst, MA) eluted 
with 1,1,1,3,3,3-hexafluoroisopropanol containing 0.01 M tetraethyl ammonium 
nitrate at a flow rate of 1.0 mL/min. Particle size was measured using dynamic 
light scattering with a Malvern ZetaSizer Nano-ZS system (Malvern Instruments 
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Ltd, Worcestershire, UK). Zeta potential was determined using a ZetaPlus 
Analyzer (Brookhaven Instruments Corp., Holtsville, NY). 
 
2.2 2-Aminoethyl 2-Bromoisobutyrate 
A solution of t-Boc-aminoethyl alcohol (50 g, 0.31 mol) and triethylamine 
(34.5 g, 0.34 mol) in 300 mL of methylene chloride was cooled in an ice bath. 
Into the solution was added 2- bromoisobutyryl bromide (71.3 g, 0.31 mol) in 150 
mL of methylene chloride. The reaction was slowly warmed to room temperature 
and stirred for 4 h. The salt was filtered off and the reaction mixture was 
extracted sequentially with water and saturated sodium bicarbonate solution. 
The organic phase was dried over magnesium sulfate. Solvent was evaporated 
and the crude product was purified by column chromatography using 
heptane/diethyl ether (80/20, w/w) as an eluent to give 65 g of t-Boc-aminoethyl 
2-bromoisobutyrate as a white solid (yield 92%). 1H NMR (CDCl3) δ (ppm): 1.45 
(s, 9 H), 1.95 (s, 6 H), 3.42–3.48 (m, 2 H), 4.24 (t, J = 5.25 Hz, 2 H). t-Boc-
aminoethyl 2-bromoisobutyrate (5.00 g, 0.016 mol) was treated with 15 mL of 
trifluoroacetic acid under vigorous stirring to remove the t-Boc protection group. 
After the reaction, excess trifluoroacetic acid was removed and the crude 
product was dried under a vacuum overnight. The crude product was stirred with 
a mixture of hexane and ethyl acetate and filtered to give 3.18 g of trifluoroacetic 
acid salt of 2-aminoethyl 2-bromoisobutyrate as a white crystalline powder (yield 
94%). 1H NMR (CDCl3) δ (ppm): 1.93 (s, 6 H), 3.35 (s, br, 2 H), 4.46 (t, J = 5.1 
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Hz, 2 H), 8.10 (s, br, 3 H); 13C NMR (CDCl3) δ (ppm): 30.24, 38.76, 55.52, 61.99, 
161.49, 161.96, 162.43, 162.90, 171.78. 
 
2.3 Block Copolymer PPEGMA-b-PESPMA (x = 31, y = 46) 
A 50-mL 3-neck flask was equipped with an additional funnel, a stopper, 
and a septum. Trifluoroacetic acid salt of 2-aminoethyl 2-bromoisobutyrate 
(0.106 g, 0.33 mmol) and bipyridine (174 mg, 1.11 mmol) were dissolved in 2.4 
mL of dry methanol in the flask, and methoxy-PEG methacrylate (PEG-MA, MW 
475) (4.8 g, 0.01 mol) was added. Triethoxysilylpropyl methacrylate (ESP-MA) 
(vacuum distilled from CaH2) (4.5 mL, 4.41 g, 0.015 mol) was placed in the 
additional funnel with 2.0 mL of dry methanol. Both mixtures in the flask and 
additional funnel were degassed by bubbling nitrogen for 15 min. Then CuBr (80 
mg, 0.56 mmol) was added quickly to the flask, and the solution turned dark 
brown. The flask was heated in an oil bath at 50°C for 30 minutes and ESP-MA 
solution was added quickly to the flask. The polymerization was continued 
overnight at 50°C. The polymerization mixture was then diluted with dry THF, 
passed through a pad of celite and basic aluminum twice, and concentrated to 
yield a clear, viscous semi-solid. 1H NMR indicated the ratio of x/y to be close to 
1/1.5. 1H NMR (300 MHz, CDCl3) δ (ppm): 0.55 (s, br), 0.77 (s, br), 0.95 (s, br), 
1.18 (t, CH3 from Si (OCH2CH3)), 1.64 (s, br), 1.96 (s, br), 3.31 (s, OMe), 3.58 (s, 
br, PEG), 3.75 (m, CH2 from Si(OCH2CH3)), 4.01 (s, br). 
 
 
~ 26 ~ 
 
2.4 CCPM Nanoparticles 
The overall process consisted of two steps. Polymeric micelles were first 
formed upon the gradual addition of distilled water into a THF solution of the 
block copolymer and Cy7-like dye 3-(triethoxysilyl)propyl-Cy7. This was followed 
by the addition of acetic acid to induce a crosslinking reaction among ethoxysilyl 
groups. Briefly, block copolymer PPEGMA-b-PESPMA (100 mg) and 3-
(triethoxysilyl) propyl-Cy7 (0.4 mg) were dissolved in 10 mL of THF. 10 mL of 
distilled water was then added slowly to the THF solution. The mixture was 
stirred at room temperature in the dark for 8 h, 0.05 mL acetic acid was added, 
and the mixture was stirred again at room temperature overnight. For 
purification, the nanoparticle-containing solution was dialyzed against distilled 
water for 24 h (MW cutoff, 3000). The solution was then filtered sequentially 
through 0.7, 0.45, 0.2, and 0.1 μm filters. The solution could be concentrated to 
the desired concentration by centrifugal filtration using a membrane with a 
molecular weight cutoff of 30,000. 
 
2.5 DTPA-Conjugated CCPM Nanoparticle 
An aqueous solution of CCPM nanoparticles (20 mL, 9.3 mg dry 
weight/mL water) was placed in an amber vial. The pH of the solution was 
adjusted to 7.5 using 2% sodium bicarbonate solution. DTPA-Bz-NCS (0.6 mg, 1 
mg/mL water) was added to the vial. The reaction was stirred under nitrogen 
overnight. Unreacted DTPA-Bz-NCS was removed by centrifugal filtration using 
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a membrane with a molecular weight cutoff of 30,000. Approximately 70% of the 
DTPA used was attached to the particles. 
 
3. Annexin A5-Conjugated CCPM  
3.1 Conjugation of Annexin A5 to CCPM  
 
 
Figure 6. Reaction scheme for the conjugation of annexin A5 to CCPM and 
radiolabeling of the resulting annexin A5-CCPM. (Reprinted with permission of 
(144)) 
 
 
 
The reaction scheme for the conjugation of annexin A5 to the surface of 
CCPM is shown in Figure 6. To introduce maleimide group to CCPM, an aliquot 
of N-[γ-maleimidobutyryloxy]-succinimide ester (GMBS) in dimethylformamide 
(22.5 µL, 7 µmol/mL, 0.16 µmol) was added into CCPM (250 µL, 2.6 nmol 
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nanoparticles) in 1.2 mL of phosphate-buffered saline (PBS, pH 8). The mixture 
was stirred for 3 h at 37°C. The product was purified using a PD-10 column to 
remove unreacted GMBS. To introduce sulfhydryl group to annexin A5, an 
aliquot of N-succinimidyl S-acetylthioacetate in dimethyl sulfoxide (26.4 µL, 50 
nmol/mL, 1.3 µmol) was added into annexin A5 (2.4 mg, 0.06 µmol) in 4.5 mL of 
PBS (pH 8). The mixture was stirred for 12 h at 4°C, and then hydroxylamine in 
water (0.5 mL, 0.5 M) was added to the solution to remove the protecting group. 
The reaction mixture was stirred for an additional 2 h and was concentrated to 1 
mL by ultracentrifugation (MWCO, 10K; Millipore Corp., Bedford, MA). After 
being passed through a PD-10 column to remove small-molecular-weight 
contaminants, the resulting sulfhydryl-containing annexin A5 was mixed with 2 
mL of PBS solution of CCPM-maleimide (0.16 µmol equivalent maleimide) with a 
molar ratio of annexin A5 to maleimide groups (CCPM) of 1:2. The solution was 
stirred for 12 h at 4°C and then purified using a fast protein liquid 
chromatography system (Amersham Pharmacia Biotech, Sweden) equipped 
with a G200 column and an ultraviolet light detector (280 nm). The column was 
eluted with PBS to remove unreacted annexin A5. The unreacted annexin A5 
was quantified using a protein assay kit (Bio-Rad, Hercules, CA) according to 
the manufacturer’s protocol, and the data were used to calculate the molar ratio 
of annexin A5 bound to CCPM in annexin A5-CCPM.  
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3.2 Characterization of Annexin A5-CCPM.  
For transmission electron microscopic examination, a drop of aqueous 
sample solution was placed on a 400-mesh copper grid coated with 0.5% 
poly(vinyl formal) aqueous solution (w/w). Negative staining was performed 
using a droplet of 1% uranyl acetate solution. The sample was air-dried and 
examined with a JEM 1010 transmission electron microscope (JEOL USA, Inc., 
Peabody, MA) at an accelerating voltage of 80 kV. Digital images were obtained 
using the AMT Imaging System (Advanced Microscopy Techniques Corp., 
Danvers, MA). Fluorescence spectra were recorded using a Fluorolog 
fluorometer (Horiba, Edison, NJ). 
 
4. Radiolabeling.  
Aliquots of annexin A5-CCPM in 0.1 M sodium acetate solution (pH 5.2) 
were mixed with an aqueous solution of 111InCl3 at room temperature for 30 min. 
Radiolabeled nanoparticles were analyzed using an instant thin-layer 
chromatography system. The instant thin-layer chromatography strips were 
developed with PBS (pH 7.4) containing 4 mM EDTA and quantified using a 
Bioscan IAR-2000 TLC Imaging Scanner (Washington, DC). Free 111In3+ moved 
to the solvent front (Rf = 0.9), and the nanoparticles remained at the original 
spot (Rf = 0.0).  
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5. Cell Culture 
DLD-1 human colorectal adenocarcinoma cells, EL4 murine lymphoma 
cells, 38C13 murine lymphoma cells, 9L rat gliosarcoma cells, and MDA-MB468 
human breast cancer cells, were obtained from American Type Cell Culture 
(Rockville, MD). Cells were maintained at 37°C in a humidified atmosphere 
containing 5% CO2 in Dulbecco’s modified Eagle’s medium and nutrient mixture 
F-12 Ham (DMEM/F12) (Gibco, Carlsbad, CA) supplemented with 10% fetal calf 
serum and a mixture of antibiotics (100 units mL-1 penicillin, 0.1 mg mL-1 
streptomycin; Biochrom AG, Holliston, MA). 
 
6. Fluorescence Microscopy 
 DLD-1 human colorectal adenocarcinoma cells were treated with tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) (Sigma-Aldrich) (200 
µL, 150 ng/mL) for 2 h to induce apoptosis. The cells were then incubated with 
annexin A5-CCPM or annexin A5-CCPM plus annexin A5 (100-fold excess) in 
HEPES binding buffer (25 mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 
7.4) for 15 min at 37°C at a final concentration of 20 nM nanoparticles. 
Untreated DLD-1 cells were used as a control. Cells were washed 3 times with 
HEPES binding buffer and cell membrane stained with wheat germ agglutinin-
Alexa Fluor 594 (Invitrogen, Carlsbad, CA). The cell samples were transferred 
onto Lab-Tek II chambered cover glass and visualized under a Zeiss Axio 
Observer.Z1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, 
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Thornwood, NY) equipped with Cy7 filters (wavelength 710/810 nm) and 
rhodamine filters (wavelength 570/620 nm).  
 
7. Cell Binding Study 
 To study cell uptake of 111In-labeled annexin A5-CCPM, DLD-1 cells were 
grown in 6-cm petri dishes to subconfluent densities in DMEM/F12 containing 10% 
fetal bovine serum 1 day before experiments. DLD-1 cells were treated with 
TRAIL at doses of 1.5 ng/mL, 15 ng/mL, and 150 ng/mL for 2 h to induce 
apoptosis. After treatment with TRAIL, the medium was replaced with 2 mL of 
fresh medium containing 111In-labeled annexin A5-CCPM nanoparticles (~1.8 
MBq/mL), and cells were incubated for 15 min. The cell monolayers were 
scraped and transferred into 5-mL tubes, and the tubes were briefly vortexed. 
Aliquots of DLD-1 cell suspension (100 µL) were transferred into a 
microcentrifuge tube containing 500 µL of a 75:25 mixture of silicon oil (density 
1.05, Aldrich) and mineral oil (density 0.872, Acros). The mixture was 
centrifuged at 14,000 rpm for 5 min. After the tubes were frozen with liquid 
nitrogen, the bottom tips containing the cell pellet were cut off. The cell pellets 
and the supernatants were counted with a γ-counter (Perkin-Elmer). The protein 
content in 100 μL of cell suspension was quantified in a separate experiment 
using a Bio-Rad protein assay kit according to the manufacturer’s protocol. 
Activity ratios of the cell pellet to medium ([cpm/µg of protein in pellet]/[cpm/µg of 
medium]) were calculated. The experiments were performed in pentaplicate. In a 
separate study, aliquots of DLD-1 cell suspension (500 µL) after TRAIL 
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treatment were transferred into microcentrifuge tubes, annexin A5-fluorescein 
isothiocyanate (FITC) was added to the tubes, and the percentage of apoptotic 
cells was analyzed using a Becton-Dickinson FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA).  
 
8. Red Blood Cell Binding Study 
Membrane lipid scrambling of red blood cell (RBC) was induced by 
calcium and ionophore treatment as described by Kuypers (145). Briefly, RBCs 
were first equilibrated in the buffer with1 mmol/L calcium for 5 min at 37°C 
before experiment. Then RBCs were incubated with calcium and ionophore with 
a concentration of 4 pmol/L for 1 h. After incubation, RBCs were washed once 
with 2.5 mmol/L EDTA to remove calcium, and then washed 3 times with 
HEPES buffer containing 1 % bovine serum albumin (BSA) to remove ionophore. 
RBCs were suspended in HEPES buffer to a final concentration of 5 X 106 /mL 
for annexin A5-CCPM binding study. Aliquots of RBC suspension (100 µL) were 
incubated with 111In-labeled annexin A5-CCPM in HEPES binding buffer (25 mM 
HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4) for 30 min at room 
temperature, at a final concentration of 100 nM, 200 nM, 300 nM, 400 nM, 500 
nM, and 600 nM nanoparticles. In the blocking group, aliquots of RBC 
suspension (100 µL) were co-incubated with 111In-labeled annexin A5-CCPM at 
above 6 concentrations and cold annexin A5 (100-fold excess). After incubation, 
the samples were centrifuged at 14,000 rpm for 10 min. The cell pellets were 
subsequently washed 3 times with HEPES buffer to remove unbound annexin 
~ 33 ~ 
 
A5-CCPM and counted with a γ-counter (Perkin-Elmer). Radioactivity counts 
(cpm) of the cell pellets were calculated and plotted against concentration. The 
experiment was performed in triplicate. 
 
9. Pharmacokinetic Study 
 All animal studies were carried out in the Small Animal Imaging Facility at 
The University of Texas MD Anderson Cancer Center in accordance with 
institutional guidelines. For the pharmacokinetic study, healthy female Swiss 
mice (22–25 g; Charles River Laboratories, Wilmington, MA) (n = 8) were 
injected intravenously at a dose of 5 × 1013 111In-labeled annexin A5-CCPM or 
111In-labeled plain CCPM per mouse (1.8 MBq/mouse). At predetermined 
intervals, blood samples (10 μL) were taken from the tail vein, and the 
radioactivity of each sample was measured with a Cobra Autogamma counter 
(Packard, Downers Grove, IL). The blood pharmacokinetic parameters for the 
radiotracer were analyzed using a noncompartmental model with WinNonlin 
5.0.1 software (Pharsight Corp., Palo Alto, CA).  
 
10. EL4 lymphoma Apoptosis Model 
Apoptosis of EL4 lymphoma was induced as described previously (10). 
Briefly, EL4 cells (1.0 x 106) were inoculated subcutaneously in the right flank of 
6- to 8-week-old syngeneic C57BL/6 mice. Two weeks after inoculation, when 
tumors reached approximately 5-6 mm in diameter, mice were divided into 4 
groups. Mice in group 1, 3, and 4 were given intraperitoneal injection of 25 
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mg/kg cyclophosphamide and 19 mg/kg etoposide. Mice in group 2 were not 
treated and were used as a control group. Mice in groups 1 and 2 received 
intravenous injection of 111In-labeled annexin A5-CCPM 1 day after drug 
treatment (n = 7 per group). Mice in group 3 received 99mTc-HYNIC-annexin A5, 
mice in group 4 received 111In-labeled CCPM 1 day after drug treatment (n = 5 
per group). At 48h after administration of 111In-labeled annexin A5-CCPM, mice 
in group 1 and 2 underwent a series of studies, including radionuclide imaging, 
optical imaging, biodistribution, autoradiography and histological analysis. 
In comparison the uptake value of in apoptotic tumor, mice in group 3 
injected with 99mTc-HYNIC-annexin A5 were killed at 6 h after radiotracer 
injection, and mice in group 4 injected with 111In-labeled CCPM were killed at 48 
h after administration of particles.  
 
11. 38C13 lymphoma Apoptosis Model 
Apoptosis of 38C13 murine lymphoma was induced as described 
previously (11). Briefly, 38C13 cells (1.0 x 106) were inoculated subcutaneously 
in the right flank of 6–8 week-old female C3H/ HeNCrl mice (22–25 g; Charles 
River Laboratories, Wilmington, MA). Two weeks after inoculation when tumors 
reached 5~6 mm in diameter, mice were divided to two groups (n = 6 per group). 
Mice in the chemotherapy group were given intraperitoneal injection of 100 
mg/kg cyclophosphamide. Mice in the control group were untreated. 111In-
labeled annexin A5-CCPM (1 × 1014 particles/mouse, 9.2 MBq/mouse) was 
injected intravenously via the tail vein 1 day after drug treatment. At 48 h after 
~ 35 ~ 
 
administration of 111In-labeled annexin A5-CCPM, the mice underwent a series 
of studies, including radionuclide imaging, optical imaging, biodistribution, 
autoradiography and histological analysis. 
 
12. 9L Gliosarcoma Tumor Apoptosis Model 
Induction of apoptosis in 9L gliosarcoma tumor model was achieved as 
described previously (12). Briefly, 9L rat gliosarcoma cells (1.0 x 106) were 
inoculated subcutaneously in the right flank of 6- to 8-week-old female nude 
mice. Three weeks after inoculation, when tumors reached approximately 5-6 
mm in average diameter, mice were divided into 2 groups (n = 6 per group). 
Mice in chemotherapy group were given intraperitoneal injection of 170 mg/kg 
cyclophosphamide. Mice were not treated as a control group. 111In-labeled 
annexin A5-CCPM (1 × 1014 particles/mouse, 9.2 MBq/mouse) was injected 
intravenously via the tail vein 1 day after the injection of cyclophosphamide. At 
48 h after administration of 111In-labeled annexin A5-CCPM, the mice underwent 
a series of studies, including radionuclide imaging, optical imaging, 
biodistribution, autoradiography and histological analysis. 
 
13. MDA-MB-468 Breast Tumor Apoptosis Model 
Induction of apoptosis in an MDA-MB-468 breast cancer model was 
achieved as described previously (13). Briefly, MDA-MB-468 human breast 
cancer cells (1 x 106) were inoculated subcutaneously in the right flank of 6- to 
8-week-old female nude mice. Four weeks after inoculation, when tumors 
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reached approximately 5-6 mm in average diameter, mice were divided into 2 
groups (n = 2 per group). Mice in group 1 were given a single intravenous 
injection of poly(L-glutamic acid)-paclitaxel at a dose of 100 mg eq. paclitaxel/kg 
on day 1 and a single intraperitoneal injection of cetuximab  (Imclone Systems, 
New York, NY), a monoclonal antibody directed against epidermal growth factor 
receptor, at a dose of 1 mg on day 4. Mice in group 2 were not treated and were 
used as a control group. 111In-labeled annexin A5-CCPM (1 × 1014 
particles/mouse, 9.2 MBq/mouse) was injected intravenously via the tail vein 1 
day after the injection of cetuximab. At 48 h after administration of 111In-labeled 
annexin A5-CCPM, the mice underwent a series of studies, including 
radionuclide imaging, optical imaging, autoradiography and histological analysis. 
 
14. Hepatic Apoptosis Model 
Induction of hepatic apoptosis was achieved as described (14). Healthy 
female BALB/c mice (22–25 g; Charles River Laboratories, Wilmington, MA) 
were divided into 3 groups (n=7 per group). Mice in group 1 and 3 were injected 
intravenously with a purified anti-Fas monoclonal antibody (10 µg/mouse, Jo2, 
Pharmingen, San Diego, CA). The mice in group 2 injected with PBS were used 
as a control group. One and half hour after administration of anti-Fas antibody or 
PBS, Mice in group 1 and 2 received intravenous administration of 111In-labeled 
annexin A5-CCPM. To further assess the binding specificity, mice in group 3 
treated with anti-Fas antibody were injected intravenously with 111In-labeled 
CCPM as another control. At 3 h after administration of 111In-labeled 
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nanoparticles, the mice underwent a series of studies, including radionuclide 
imaging, optical imaging, biodistribution, autoradiography and histological 
analysis. 
 
15. Inflammation Model 
Healthy female SWISS mice (22–25 g; Charles River Laboratories, 
Wilmington, MA) received a deep intramuscular injection of 100 µL of 100% pure 
gum turpentine (Spectrum, New Brunswick, NJ) in the right thigh of mice. The 
left thigh served as an internal control for nonspecific thigh uptake of tracer. Mice 
were divided into 2 groups (n=5 per group). In group 1, at 24 h after the 
administration of turpentine, 111In-labeled annexin A5-CCPM was injected 
intravenously. Mice in group 2 were injected with 111In-labeled CCPM as another 
control. At 48 h after administration of 111In-labeled nanoparticles, the mice 
underwent a series of studies, including radionuclide imaging, optical imaging, 
biodistribution, autoradiography and histological analysis. 
 
16. Imaging and Biodistribution Studies 
In above 6 models, at respective time point after administration of 111In-
labeled annexin A5-CCPM or CCPM nanoparticles, single photon computed 
tomography (SPECT) and computed tomography (CT) images were acquired 
using an xSPECT-CT scanner (Gamma Medica, Northridge, CA). SPECT 
(radius of rotation 3 cm, 32 projections, 20 s per projection) and CT scans (512 
projections, 75 kV, 500 mA) were acquired and co-registered for image fusion 
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and presentation of 3D anatomical localization of the tracer signal. Acquired 
SPECT and CT data sets were processed with AMIRA 5.1 (San Diego, CA). The 
whole-body optical imaging was performed using fluorescent molecular 
tomography (FMT, Visen, Bedford, MA) equipped with 760/790 nm 
excitation/emission wavelength filter. During each imaging session, mice were 
anesthetized with 2% isoflurane gas (Iso-Thesia, Rockville, NY) in oxygen.  
By the end of the imaging sessions, mice were killed, and various tissues 
were removed, weighed, and counted for radioactivity with a Cobra Autogamma 
counter (Packard, Downers Grove, IL). Uptake of the nanoparticles was 
calculated as the percentage of the injected dose per gram of tissue (%ID/g). 
Additionally in EL4 lymphoma apoptosis model, fluorescence images of dissected 
tissues were acquired using an IVIS imaging system (Xenogen Corp., Alameda, CA) 
equipped with indocyanine green filter sets (excitation/emission, 710-760/810-875 nm). 
Fluorescence intensities were calculated using LIVINGIMAGE v.2.11 software 
(Xenogen). Uptakes of the nanoparticles in various tissues were calculated as flux 
(photons/s) per gram of tissue. Student’s t test was used to compare differences in 
tissue uptakes between different groups, and p values less than 0.01 were 
considered highly significant. 
 
17. Autoradiography and Optical Imaging 
 Tumors harvested at the end of the imaging sessions were snap-frozen 
and sectioned into 5-µm sections. The sections were photographed and 
exposed on BAS-SR 2025 Fuji phosphorous films. The film was scanned with a 
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FLA5100 Multifunctional Imaging System (Fujifilm Medical Systems USA, 
Stamford, CT).  
 After autoradiographic study, optical images of the sections were 
acquired by scanning at 800 nm using an Odyssey infrared imaging system (LI-
COR Biosciences, Lincoln, NE). 
 
18. Immunohistochemistry 
In EL4 and 38C13 lymphoma models, following autoradiographic study, 
one slice of each tumor was immunostained with anti-caspase-3 antibody by 
using a commercial kit (Sigma, St. Louis, MO) according to the manufacturer’s 
protocol. The stained sections were counterstained with hematoxylin. Image was 
recorded by a Zeiss Axio Observer.Z1 microscope.  
In all 4 tumor apoptosis models, for terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL), a slide adjacent to those used for 
autoradiographic studies was stained with a TUNEL staining kit (R&D Systems, 
Minneapolis, MN) according to manufacturer’s instruction. Cell nuclei were 
counterstained with 4'-6-Diamidino-2-phenylindole (DAPI). The cellular 
fluorescence was examined under a Zeiss Axio Observer.Z1 fluorescence 
microscope equipped with UV filter for DAPI, 494/517 nm filter for TUNEL 
staining, and 710/810 nm for Cy7. 
In the models of hepatic apoptosis and inflammation, following 
autoradiographic study, one slice of each tissue (liver or thigh) received 
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Hematoxylin and Eosin (H&E) staining. Image was recorded by a Zeiss Axio 
Observer.Z1 microscope.  
 
19. Statistical Analysis 
 Statistical analysis was performed with GraphPad Prism v4.0 software 
(La Jolla, CA). Unless otherwise stated, group comparisons were made using 
standard ANOVA methods. Groups with P < 0.01 were considered highly 
significant.  
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RESULTS 
 
1. Characterization of CCPM Nanoparticles 
Table 5 showed physicochemical properties of CCPM nanoparticles. 
According to previous report by Dr. Zhi Yang (143), each CCPM nanoparticle 
contained approximately 21 Cy7-like dye molecules, 180 amino (NH2) groups 
and 19 DTPA molecules. 
 
 
Table 5. Summary of physicochemical properties of CCPM nanoparticles. 
(Reprinted with permission of (143)) 
 
 
 
2. Characterization of Annexin A5-CCPM Nanoparticles 
Figure 7A is a transmission electron microscopic image of annexin A5-
CCPM. The excitation and emission light intensities for the annexin A5-CCPM 
nanoparticles peaked at 755 nm and 781 nm, respectively (Fig. 7B). The 
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average diameter of the nanoparticles was 25 nm on the basis of transmission 
electron microscopy images. After purified using FPLC (Fig. 7D), each annexin 
A5-CCPM nanoparticle contained approximately 40 annexin A5 molecules on 
the surface calculated on the basis of the molar feed ratio. As indicated by 
instant thin-layer chromatography, the labeling efficiency of annexin A5-CCPM 
was greater than 98% without further purification (Fig. 7C). The specific activity 
was 185 MBq/nmol nanoparticles. 
 
 
Figure 7. Characterization of annexin A5-CCPM nanoparticles. (A) 
Transmission electron micrograph of annexin A5-CCPM nanoparticles. (B) 
Absorbance and emission spectra of CCPM before and after introduction of 
annexin A5. (C) ITLC result of 111In-labeled annexin A5-CCPM. (D) FPLC result 
of annexin A5-CCPM after purification. 
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3. Fluorescence Microscopy 
 
 
Figure 8. Fluorescence microphotographs of DLD-1 human colon cancer cells 
after exposure to annexin A5-CCPM. DLD-1 cells were treated with TRAIL (150 
ng/mL) followed by 111In-labeled annexin A5-CCPM 2 h later (left);  TRAIL 
followed by 111In-labeled annexin A5-CCPM plus annexin A5 (100-fold excess) 2 
h later (middle); or PBS followed by 111In-labeled annexin A5-CCPM 2 h later 
(right).  Signal from Cy7-loaded CCPM is pseudocolored green. Cell membrane 
was stained with Alexa Fluor 594-labeled wheat germ agglutinin (WGA) (red), 
and cell nuclei were stained with DAPI (blue).  
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Figure 8 shows fluorescence microscopic images of viable human DLD-1 
colon cancer cells and apoptotic DLD-1 cells incubated with annexin A5-CCPM. 
The membrane of both TRAIL- and PBS-treated cells was stained red with 
wheat germ agglutinin-Fluor594. However, only TRAIL-treated cells showed 
binding of annexin A5-CCPM to the cell membrane. Moreover, the binding of 
annexin A5-CCPM to the apoptotic cells was efficiently blocked by annexin A5 
(Fig. 8). 
 
4. Cell Binding Study 
TRAIL-induced apoptosis in DLD-1 cells was analyzed by flow cytometry 
at TRAIL concentrations of 1.5-150 ng/mL using FITC-annexin A5 (Fig. 9A). 
There was a sharp increase in the apoptotic response when TRAIL 
concentration increased from 15 to 150 ng/mL, and the percentage of apoptotic 
cells increased from 3.76% to 24.5%. When 111In-labeled annexin A5-CCPM 
was incubated with TRAIL-treated DLD-1 cells, increasing amount of the 
radiotracer was bound to the cells in a TRAIL dose-dependent manner (Fig. 9B). 
A significant increase in cell-associated radioactivity was detected at a TRAIL 
dose of 1.5 ng/mL. The binding of 111In-labeled annexin A5-CCPM to apoptotic 
cells was completely blocked by an excess of annexin A5 (Fig. 9B). These 
results confirmed that 111In-labeled annexin A5-CCPM selectively bound to PS 
on the surface of apoptotic cells.  
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Figure 9. Uptake studies of DLD-1 human colon cancer cells after exposure to 
111In-labeled annexin A5-CCPM. (A) DLD-1 cells were incubated with TRAIL for 
2 h at the indicated doses, stained with annexin A5-FITC, and assayed for the 
percentage of apoptotic cells using flow cytometry. (B) DLD-1 cells were 
incubated with TRAIL for 2 h at the indicated doses and then incubated with 
111In-labeled annexin A5-CCPM without or with annexin A5 (100-fold excess) for 
15 min. The data are expressed as cpm/µg protein in cell pellet over cpm/µg 
medium and presented as mean ± standard deviation (n = 5). * Indicates 
statistically significant change in values with P <0.001. 
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5. Red Blood Cell Binding Study 
It has been reported that radioactive or fluorescent annexin A5 could be 
used as a probe to detect RBCs that have lost phospholipid asymmetry (145). 
Figure 10 showed that binding curves of 111In-labeled annexin A5-CCPM to 
RBCs without and with excess annexin A5. When 111In-labeled annexin A5-
CCPM was incubated with RBCs, increasing amounts of the nanoparticles 
bound to the cells in a dose-dependent manner. In contrast, little binding to 
RBCs was detected in the presence of excess annexin A5, suggesting that the 
binding was efficiently blocked by excess amount of annexin A5.  
 
 
Figure 10. The binding study of 111In-labeled annexin A5-CCPM to RBCs. RBCs 
were incubated with 111In-labeled annexin A5-CCPM at the indicated doses 
without or with annexin A5 (100-fold excess) for 30 min. The data are expressed 
as radioactivity counts (cpm) of cell pellets and presented as mean ± standard 
deviation (n = 3).  
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6. Pharmacokinetics 
 
 
Figure 11. Blood activity-time profiles of 111In-labeled annexin A5-CCPM and 
plain CCPM. The open circles represent the mean radioactivity expressed as a 
percentage of the injected dose per gram of blood from 7 mice. Data for CCPM 
were taken from reference (143). 
 
 
 Figure 11 compares the activity-time profiles of 111In-labeled annexin A5-
CCPM and plain CCPM. Data for CCPM were taken from reference (143). The 
plain CCPM showed a bi-exponential disposition, whereas 111In-labeled annexin 
A5-CCPM appeared to have a single exponential disposition following 
intravenous administration. Mean pharmacokinetic parameters are summarized 
in Table 6. Introduction of annexin A5 to CCPM resulted in a significantly shorter 
mean terminal elimination half-life, less systemic exposure (total area-under-the-
bloodconcentration versus time curve), and smaller mean volume of distribution 
at steady-state as compared with unmodified CCPM. The mean systemic 
clearance was significantly slower with the unmodified CCPM (0.0902 mL/h) 
than with 111In-labeled annexin A5-CCPM (0.217 mL/h, P <0.001), suggesting 
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that 111In-labeled annexin A5-CCPM was cleared more than twice as fast as the 
unmodified CCPM. This can be attributed to higher elimination by the liver 
and/or spleen of 111In-labeled annexin A5-CCPM than of CCPM. For both 111In-
labeled CCPM and annexin A5-CCPM, mean volume of distribution at steady-
state was similar to mean volume of distribution in the central compartment, 
indicating that both agents mainly distributed to the central compartment 
(systemic blood circulation). 
 
Table 6. Comparison of mean ± standard deviation pharmacokinetic parameters for 
plain CCPM and 111In-labeled annexin A5-CCPM in mice. aT1/2 = terminal biological half-
life; AUC = total area under the blood concentration versus time curve; Cmax = predicted 
maximum drug concentration in blood; %ID = percentage of injected dose; Vd = 
apparent volume of distribution; Vss = steady-state volume of distribution; CL = total 
body clearance; MRT = mean residence time.  P values were obtained using a 2-
sample t test. 
Parametera CCPM Annexin A5-CCPM P 
Number of mice 8 7 - 
T1/2 (h) 39.0 ± 8.4 12.5 ± 1.4 0.000 
AUC (%ID/mL blood) 1148 ± 213 466 ± 53 0.000 
Cmax (%ID/mL) 27.2 ± 3.1 22.4 ± 2.9 0.008 
Vd (mL) 4.95 ± 0.9 3.91 ± 0.64 0.024 
Vss (mL) 5.18 ± 0.65 4.44 ± 0.24 0.015 
CL (mL/h) 0.0902 ± 0.019 0.217 ± 0.023 0.000 
MRT (h) 58.7 ± 8.3  20.6 ± 1.9 0.000 
~ 49 ~ 
 
7. EL4 Lymphoma Apoptosis Model 
Treatment of mice bearing EL4 lymphoma with cyclophosphamide and 
etoposide induces substantial apoptosis (10). This model was used to study the 
effect of apoptosis on the biodistribution of 111In-labeled annexin A5-CCPM. 
Figure 12 compares µSPECT and fluorescent molecular tomography optical 
images of mice with and without treatment of cyclophosphamide/etoposide 
regimen obtained 48 h after administration of 111In-labeled annexin A5-CCPM. 
The apoptotic tumor was clearly visualized after chemotherapy in these mice 
with EL4 lymphoma (Figs. 12A and 12B). In contrast, there was little signal in 
the tumors of untreated mice (Figs. 14A and 12B). Intratumoral distribution of 
111In-labeled annexin A5-CCPM was shown in both autoradiographic images 
(Fig. 12C) and fluorescence optical images of tumor sections (Fig. 12D). 
Chemotherapy caused markedly increased radioactivity and fluorescent signal 
intensity in the tumors. Localization of both radioactivity and fluorescence signal 
from 111In-labeled annexin A5-CCPM correlated with apoptotic cells stained with 
caspase-3 antibody (Figs. 12C-12F). Moreover, fluorescence microscopy 
showed that the fluorescent signal from 111In-labeled annexin A5-CCPM co-
localized with apoptotic cells detected with TUNEL assay (Fig. 13).  
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Figure 12. Dual SPECT/CT and near-infrared fluorescence optical imaging of 
EL4 lymphoma apoptosis with 111In-labeled annexin A5-CCPM. The mice in the 
control group (top) were injected intravenously only with 111In-labeled annexin 
A5-CCPM. The mice in the chemotherapy group (bottom) received an 
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with 
cyclophosphamide 25 mg/kg by intraperitoneal (i.p.) injection and etoposide 19 
mg/kg by i.p. injection. (A) Representative SPECT/CT images. (B) 
Representative fluorescence molecular tomographic images. (C) Representative 
autoradiographs of excised tumors. (D) Fluorescence images of the same slides 
used in autoradiographic studies. (E and F) Immunohistochemical staining with 
caspase-3 (brown) of the same slides used in autoradiographic studies. All 
images were acquired 48 h after injection of 111In-labeled annexin A5-CCPM.  
Bar, 50 µm. 
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Figure 13. Fluorescence microscopy of EL4 lymphoma from mice treated with 
chemotherapy. The tumor sections were subjected to TUNEL staining (red). 
Signal from Cy7 loaded annexin A5-CCPM was pseudocolored green and cell 
nuclei were stained with DAPI (blue). Scale bar: 50 µm.  
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The biodistribution data (Fig. 14A) were generally in concordance with 
the imaging result (Fig. 12): there was relatively high accumulation in the liver 
and spleen. Spleens of the mice treated with chemotherapy showed significantly 
higher uptake of 111In-labeled annexin A5-CCPM than spleens in the control 
group (P <0.001), probably owing to cyclophosphamide-induced apoptosis of 
this tissue (83). At 48 h after injection, 111In-labeled annexin A5-CCPM showed 
significantly higher uptake in the tumors of the treated mice (8.01 %ID/g) than in 
the tumors of the untreated mice (3.2 %ID/g) (P <0.001) (Fig. 14A). The tumor-
to-blood ratios were 2.2 in the untreated group versus 4.1 in the chemotherapy-
treated group, and the tumor-to-muscle ratios were 14.8 in the untreated group 
versus 38.8 in the chemotherapy-treated group. 111In-labeled annexin A5-CCPM 
(8.01 %ID/g) also showed significantly higher uptake in the tumors of the treated 
mice than 99mTc-HYNIC annexin A5 (4.14 %ID/g) and 111In-labeled CCPM 
(2.81 %ID/g) (P <0.001) (Fig. 14B). The biodistribution was also determined by 
analysis of fluorescence signal intensities of the resected tissues (Fig. 15), 
which were consistent with the data obtained by the radioactivity count method 
(Fig. 14A).  
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Figure 14. Biodistribution in mice bearing EL4 lymphoma. (A) Biodistribution 48 
h after the administration of 111In-labeled annexin A5-CCPM. The mice in the 
chemotherapy group were injected with 111In-labeled annexin A5-CCPM 
intravenously 24 h after administration of cyclophosphamide and etoposide. The 
mice in the control group were injected only with 111In-labeled annexin A5-CCPM. 
(B) Tumor uptake of 111In-labeled annexin A5-CCPM, 111In-labeled CCPM, and 
99mTc-HYNIC-annexin A5 in the EL4 tumor of mice treated with 
cyclophosphamide and etoposide. Data obtained using the radioactivity count 
method plotted as percentage of injected dose per gram of tissue (%ID/g). All 
the data are expressed as mean ± standard deviation. * Indicates statistically 
significant change in values with P <0.001. 
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Figure 15. Biodistribution 48 h after the administration of 111In-labeled annexin 
A5-CCPM in mice bearing EL4 lymphoma. The mice in the chemotherapy group 
were injected with 111In-labeled annexin A5-CCPM intravenously 24 h after 
administration of cyclophosphamide and etoposide. The mice in the control 
group were injected only with 111In-labeled annexin A5-CCPM. (A) 
Representative near-infrared fluorescence images of various tissues resected 
from mice at the end of the imaging session. (B) Data obtained using the 
fluorescence intensity measurement method plotted as photon count per gram of 
tissue. All the data are expressed as mean ± standard deviation (n = 7). * 
Indicates statistically significant change in values with P <0.001. 
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8. 38C13 Lymphoma Apoptosis Mode 
Treatment of mice bearing 38C13 lymphoma with cyclophosphamide 
induces substantial apoptosis (11). This model was used to further evaluate the 
potential of 111In-labeled annexin A5-CCPM for imaging tumor apoptosis. Figure 
16 compares µSPECT and FMT optical images of mice without treatment and 
mice treated with cyclophosphamide 48 h after administration of 111In-labeled 
annexin A5-CCPM. The apoptotic tumors were readily visualized in the mice 
bearing 38C13 lymphoma after treatment of cyclophosphamide, while the 
tumors in the untreated mice were not detected (Figs. 16A and 16B). Both 
autoradiographic images (Fig. 16C) and fluorescence optical images (Fig. 16D) 
of tumor sections showed Intratumoral distribution of 111In-labeled annexin A5-
CCPM. Tumor sections from chemotherapy group exhibited higher radioactivity 
and fluorescent signal intensity than tumor sections from control group, which 
was generally in concordance with whole-body scanning results. Localization of 
both radioactivity and fluorescence signal from 111In-labeled annexin A5-CCPM 
correlated with apoptotic cells stained with caspase-3 antibody (Figs. 16C-16F). 
Moreover, immunohistochemical analysis confirmed co-localization of 111In-
labeled annexin A5-CCPM and apoptotic areas (Fig. 17).  
 
~ 56 ~ 
 
 
Figure 16. Dual SPECT/CT and near-infrared fluorescence optical imaging of 
38C13 lymphoma apoptosis with 111In-labeled annexin A5-CCPM. The mice in 
the control group (top) were injected intravenously only with 111In-labeled 
annexin A5-CCPM. The mice in the chemotherapy group (bottom) received an 
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with 
cyclophosphamide 100 mg/kg by intraperitoneal injection. (A) Representative 
SPECT/CT images. (B) Representative fluorescence molecular tomographic 
images. (C) Representative autoradiographs of excised tumors. (D) 
Fluorescence images of the same slides used in autoradiographic studies. (E 
and F) Immunohistochemical staining with caspase-3 (brown) of the same slides 
used in autoradiographic studies. All images were acquired 48 h after injection of 
111In-labeled annexin A5-CCPM.  
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Figure 17. Fluorescence microscopy of 38C13 lymphoma from mice treated with 
chemotherapy. The tumor sections were subjected to TUNEL staining (green). 
Signal from Cy7 loaded annexin A5-CCPM was pseudocolored red and cell 
nuclei were counterstained with DAPI (blue). Scale bar: 20 µm. 
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The biodistribution data (Fig. 18) were consistent with imaging study (Fig. 
16). At 48 h after injection, 111In-labeled annexin A5-CCPM showed significantly 
higher uptake in the tumor of the treated mice (4.84 %ID/g) as compared to the 
untreated mice (0.49 %ID/g) (p <0.001) (Fig. 18). The tumor-to-blood ratios 
increased from 0.2 in control group to 2.8 in chemotherapy group, and the 
tumor-to-muscle ratios increased from 4.6 to 22.7. In the meantime, there was 
relatively high uptake of 111In-labeled annexin A5-CCPM in the livers and 
spleens. 
 
 
Figure 18. Biodistribution in mice bearing 38C13 lymphoma 48 h after the 
administration of 111In-labeled annexin A5-CCPM. The mice in the chemotherapy 
group were injected with 111In-labeled annexin A5-CCPM intravenously 24 h 
after administration of cyclophosphamide (black). The mice in the control group 
were injected only with 111In-labeled annexin A5-CCPM (white). Data obtained 
using the radioactivity count method plotted as percentage of injected dose per 
gram of tissue (%ID/g). All the data are expressed as mean ± standard deviation. 
* Indicates statistically significant change in values with P <0.001. 
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9. 9L Gliosarcoma Tumor Apoptosis Model 
The treatment of cyclophosphamide also can induce 9L gliosarcoma 
tumor apoptosis in mice (12). This model was used to further investigate the 
potential of 111In-labeled annexin A5-CCPM for imaging tumor apoptosis. Figure 
19 compares µSPECT and FMT optical images of mice without treatment and 
mice treated with cyclophosphamide 48 h after administration of 111In-labeled 
annexin A5-CCPM. The apoptotic tumors were clearly visualized in the mice 
bearing 9L gliosarcoma tumor after treatment of cyclophosphamide (Figs. 19A 
and 19B). In contrast, there was no detectable uptake in the tumors of the 
untreated mice (Figs. 19A and 19B). Intratumoral distribution of 111In-labeled 
annexin A5-CCPM was shown in both autoradiographic images (Fig. 19C) and 
fluorescence optical images (Fig. 19D) of tumor sections. In comparison with 
control group, chemotherapy group exhibited relatively high radioactivity and 
fluorescent signal intensity in their tumor sections, which confirmed there was 
relatively high uptake in apoptotic tumors. Furthermore, 111In-labeled annexin 
A5-CCPM co-localized with apoptotic areas stained with TUNEL (Fig. 20). 
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Figure 19. Dual SPECT/CT and near-infrared fluorescence optical imaging of 9L 
gliosarcoma tumor apoptosis with 111In-labeled annexin A5-CCPM. The mice in 
the control group (top) were injected intravenously only with 111In-labeled 
annexin A5-CCPM. The mice in the chemotherapy group (bottom) received an 
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with 
cyclophosphamide 100 mg/kg by intraperitoneal injection. (A) Representative 
SPECT/CT images. (B) Representative fluorescence molecular tomographic 
images. (C) Representative autoradiographs of excised tumors. (D) 
Fluorescence images of the same slides used in autoradiographic studies. All 
images were acquired 48 h after injection of 111In-labeled annexin A5-CCPM.   
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Figure 20. Fluorescence microscopy of 9L gliosarcoma tumor from mice treated 
with chemotherapy. The tumor sections were subjected to TUNEL staining 
(green). Signal from Cy7 loaded annexin A5-CCPM was pseudocolored red and 
cell nuclei were stained with DAPI (blue). Scale bar: 20 µm. 
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The biodistribution data (Fig. 21) generally confirmed the imaging result 
(Fig. 19). At 48 h after injection, 111In-labeled annexin A5-CCPM exhibited 
significantly higher uptake in the tumors of the chemotherapy group (6.41 %ID/g) 
than in the tumors of the control group  (2.91 %ID/g) (P <0.001) (Fig. 21). The 
tumor-to-blood ratios were 1.9 in the control group versus 3.2 in the 
chemotherapy group, and the tumor-to-muscle ratios were 7.9 in the control 
group versus 18.2 in the chemotherapy group. Similarly, there was significantly 
higher uptake of 111In-labeled annexin A5-CCPM in spleens of the mice treated 
with cyclophosphamide than in spleens of the control mice (P <0.001) (Fig. 21). 
That is probably because  cyclophosphamide induced spleen apoptosis (83). 
 
Figure 21. Biodistribution in mice bearing 9L gliosarcoma tumor 48 h after the 
administration of 111In-labeled annexin A5-CCPM. The mice in the chemotherapy 
group were injected with 111In-labeled annexin A5-CCPM intravenously 24 h 
after administration of cyclophosphamide (black). The mice in the control group 
were injected only with 111In-labeled annexin A5-CCPM (white). Data obtained 
using the radioactivity count method plotted as percentage of injected dose per 
gram of tissue (%ID/g). All the data are expressed as mean ± standard deviation. 
* Indicates statistically significant change in values with P <0.001. 
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10. MDA-MB-468 Breast Tumor Apoptosis Model 
As previously described by Ke Shi (13), MDA-MB-468 breast tumor could 
be induced apoptosis by treatment of poly (L-glutamic acid)-paclitaxel and 
cetuximab. In order to further evaluate the potential application of 111In-labeled 
annexin A5-CCPM for imaging drug-induced tumor apoptosis, this model was 
also applied in this study. Figure 22 compares µSPECT and FMT optical images 
of mice without and with chemotherapy 48 h after administration of 111In-labeled 
annexin A5-CCPM. The apoptotic tumors were readily visualized in the mice 
bearing MDA-MB-468 breast tumor after chemotherapy, while the tumors in the 
untreated mice were not detected (Figs. 22A and 22B). Both autoradiographic 
images (Fig. 22C) and fluorescence optical images (Fig. 22D) of tumor sections 
showed Intratumoral distribution of 111In-labeled annexin A5-CCPM. Tumor 
sections from chemotherapy group exhibited higher radioactivity and fluorescent 
signal intensity than tumor sections from control group, which was generally in 
concordance with results of the whole-body scanning. Moreover, 
immunohistochemical analysis confirmed co-localization of 111In-labeled annexin 
A5-CCPM and apoptotic areas stained with TUNEL (Fig. 23).  
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Figure 22. Dual SPECT/CT and near-infrared fluorescence optical imaging of 
MDA-MB-468 tumor apoptosis with 111In-labeled annexin A5-CCPM. The mice in 
the chemotherapy group (bottom) received an intravenous injection of 111In-
labeled annexin A5-CCPM after treatment with poly(L-glutamic)-paclitaxel 
conjugate (100 mg eq. paclitaxel/kg by intravenous injection; day 1) and 
cetuximab  (1 mg/mouse by intraperitoneal injection; day 4). The mice in the 
control group (top) were injected intravenously only with 111In-labeled annexin 
A5-CCPM. (A) Representative SPECT/CT images. (B) Representative 
fluorescence molecular tomographic images. (C) Representative 
autoradiographs of excised tumors. (D) Fluorescence images of the same slides 
used in autoradiographic studies. All images were acquired 48 h after injection of 
111In-labeled annexin A5-CCPM. 
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Figure 23. Fluorescence microscopy of MDA-MB-468 breast tumor from mice 
treated with chemotherapy. The tumor sections were subjected to TUNEL 
staining (red). Signal from Cy7 loaded annexin A5-CCPM was pseudocolored 
green and cell nuclei were stained with DAPI (blue). 
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11. Hepatic Apoptosis Model 
Anti-Fas antibody, which binds to hepatic Fas receptors, can be used to 
induce massive apoptosis of hepatocytes in mice within a few hours, mimicking 
fulminant hepatitis (14). In histological analysis (Fig. 24E), hepatocytes in the 
liver treated with anti-Fas antibody exhibited pyknosis of nuclei and 
condensation of the cytoplasm, which are typical features of apoptotic cell death. 
It demonstrated that anti-Fas antibody, Jo2, could rapidly induce massive 
apoptosis in the liver of mice, mimicking fulminant hepatitis. As shown in Figures 
24A and 24B, 111In-labeled annexin A5-CCPM exhibited significantly high 
accumulation in the apoptotic liver treated with anti-Fas antibody. In contrast, 
low signals were detected in healthy livers of untreated mice after injection of 
111In-labeled annexin A5-CCPM and in apoptotic livers of treated mice after 
injection of 111In-labeled plain CCPM (Figs. 24A and 24B).  Both 
autoradiographic images (Fig. 24C) and fluorescence optical images (Fig. 24D) 
of hepatic sections also showed there was relatively high signal intensity in the 
apoptotic liver after administration of 111In-labeled annexin A5-CCPM.  
The biodistribution data further confirmed the imaging results. The uptake 
values of 111In-labeled annexin A5-CCPM in apoptotic liver (35 %ID/g) was 2 
times higher than its uptake value in healthy liver (10 %ID/g) (P <0.001) (Fig. 
25). In addition, 111In-labeled annexin A5-CCPM (35 %ID/g) also showed 3 times 
higher uptake in apoptotic liver than 111In-labeled plain CCPM (7.8 %ID/g) (P 
<0.001) (Fig. 25). 
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Figure 24. Dual SPECT/CT and near-infrared fluorescence optical imaging of 
hepatic apoptosis with 111In-labeled annexin A5-CCPM. The mice received 
intravenous injection of 111In-labeled annexin A5-CCPM 2 h after treatment with 
anti-Fas antibody 10 ug/mouse (left) or PBS (middle) by intravenous injection. 
The mice were injected intravenously with 111In-labeled plain CCPM 2 h after 
anti-Fas antibody treatment (right).  (A) Representative SPECT/CT images. (B) 
Representative fluorescence molecular tomographic images. (C) Representative 
autoradiographs of excised tumors. (D) Fluorescence images of the same slides 
used in autoradiographic studies. (E) H&E staining of the same slides used in 
autoradiographic studies. All images were acquired 3 h after injection of 111In-
labeled nanoparticles. 
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Figure 25. Biodistribution in hepatic apoptosis model 3 h after the administration 
of 111In-labeled annexin A5-CCPM or 111In-labeled CCPM. The mice received 
intravenous injection of 111In-labeled annexin A5-CCPM 2 h after treatment with 
anti-Fas antibody (black) or PBS (gray) by intravenous injection. The mice were 
injected intravenously with 111In-labeled plain CCPM 2 h after anti-Fas antibody 
treatment (white). Data obtained using the radioactivity count method plotted as 
percentage of injected dose per gram of tissue (%ID/g). All the data are 
expressed as mean ± standard deviation. * Indicates statistically significant 
change in values with P <0.001. 
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12. Inflammation Model 
Turpentine can be used as a stimulus to trigger a series of inflammation 
reactions by intramuscular injection, such as migration of granulocytes to the 
injured tissues, and clearance of apoptotic granulocytes through PS-specific 
recognition by monocytes (15). In Figures 26A and 26B, the right thigh abscess 
was readily visualized by both nuclear and optical imaging after intravenous 
administration of 111In-labeled annexin A5-CCPM, whereas the left control thigh 
was not detected.  
 
 
Figure 26. Dual SPECT/CT and near-infrared fluorescence optical imaging of 
inflammation with 111In-labeled annexin A5-CCPM. The mice received 
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with 
turpentine or PBS 100 uL/mouse by intramuscular injection. (A) Representative 
SPECT/CT images. (B) Representative fluorescence molecular tomographic 
images. All images were acquired 48 h after injection of 111In-labeled annexin 
A5-CCPM. 
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Autoradiographic, fluorescence optical and histological images of muscle 
sections confirmed the intensely focal zones of 111In-labeled annexin A5-CCPM 
co-localized to the inflammatory areas with infiltration of granulocytes and less 
monocytes adjacent to abscess cavities (Figs. 27A-27C). 
 
 
 
 
Figure 27. Autoradiography, optical imaging and immunohistochemical analysisi 
of muscle section with 111In-labeled annexin A5-CCPM. The mice received 
intravenous injection of 111In-labeled annexin A5-CCPM 24 h after treatment with 
turpentine or PBS 100 uL/mouse by intramuscular injection. (A) Representative 
autoradiographs of excised tumors. (B) Fluorescence images of the same slides 
used in autoradiographic studies. (C) H&E staining of the same slides used in 
autoradiographic studies. All images were acquired 48 h after injection of 111In-
labeled annexin A5-CCPM. 
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Biodistribution data showed a general concordance with the imaging 
results, with the uptake value of 4.9 (%ID/g) in the thigh abscess after injection 
of 111In-labeled annexin A5-CCPM, as compared to the values of 0.6 (%ID/g) in 
the healthy thigh after injection of 111In-labeled annexin A5-CCPM and 2.3 
(%ID/g) in the thigh abscess after injection of 111In-labeled plain CCPM (p<0.001) 
(Fig. 28). Interestingly, 111In-labeled CCPM also exhibited higher uptake in the 
thigh abscess (2.3 %ID/g) than in the health thigh (0.4 %ID/g) (p<0.001) (Fig. 
28). 
 
 
 
Figure 28. Thigh uptake of 111In-labeled annexin A5-CCPM and 111In-labeled 
CCPM in mice treated with turpentine or PBS. Data obtained using the 
radioactivity count method plotted as percentage of injected dose per gram of 
tissue (%ID/g). All the data are expressed as mean ± standard deviation. * 
Indicates statistically significant change in values with P <0.001. 
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DISCUSSION 
 
In this study, we found that injection of 111In-labeled annexin A5-CCPM 
allowed ready visualization of drug-induced apoptosis with both SPECT and 
near-infrared fluorescence imaging in 6 different apoptosis models. Moreover, 
111In-labeled annexin A5-CCPM permitted detection of apoptotic cells at the 
microscopic level by optical imaging.  
Apoptosis is a dynamic process in which newly generated apoptotic cells 
are rapidly removed by phagocytic macrophages (146). Therefore, there is a 
short "time window" during which apoptotic cells display their characteristic 
features such as externalization of Phosphatidylserine to the outer leaflet of cell 
membrane. Generally, the time from initiation of apoptosis to completion occurs 
as quickly as 2 - 3 h. Furthermore, the peak apoptotic activity after therapy 
varies from treatment to treatment and from patient to patient. Thus, it is critical 
that apoptosis is captured at its peak or over a prolonged period during which 
apoptotic responses exists to maximize the detection sensitivity when using PS-
binding ligands. Currently, 99mTc-labeled annexin A5 is widely used in detection 
of apoptosis. Owing to its short blood half-life (<7 min) (13), it has been 
suggested that an imaging protocol using multiple separate injections of 99mTc-
labeled annexin A5 and multiple radionuclide scans could be used to assess 
peak apoptotic activity. Such a protocol, however, may be difficult to implement 
in larger-scale trials, because there probably is blocking interference between 
repetitive doses of annexin A5. It has been reported that annexin A5 can 
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strongly bind to 3 PS molecules on the cell surface with a nanomolar affinity 
(147). Thus, it is possible that the previous injection of annexin A5 may still tie 
up PS on the cell surface and thereby compromise the ability of the later dose to 
bind. We hypothesized that modulation of the pharmacokinetics of annexin A5 
through the use of long-circulating nanoparticles would permit single injection of 
this tracer to monitor apoptotic process over a prolonged period of time, avoiding 
an imaging protocol with multiple injections. On the other hand, due to short 
circulation time in vivo, 99mTc-labeled annexin A5 exhibits limited exposure time 
and penetration into tumor mass, which compromise its sensitivity. Therefore, 
the introduction of long-circulating nanoparticles permits annexin A5-
nanoparticles to penetrate deep and increase its uptake in apoptotic tissues. In 
this study, annexin A5 was conjugated to the surface of polyethylene glycol-
coated CCPM. Although introduction of annexin A5 molecules to CCPM resulted 
in significant reduction in the blood half-life of the resulting annexin A5-CCPM as 
compared to the unmodified CCPM (Table 6), the mean half-life of 12.5 h was 
still much longer than that of annexin A5. We found that while conventional 
99mTc-HYNIC annexin A5 showed an uptake value of 4.14 %ID/g in EL4 
lymphoma of the treated mice, 111In-labeled annexin A5-CCPM showed an 
uptake value of 8.01 %ID/g, indicating that prolonging the blood half of annexin 
A5 could lead to increased uptake of the radiotracer in apoptotic tumors. The 
increased tumor uptake of 111In-labeled annexin A5-CCPM was not a result of 
increased permeability and retention effect, because 111In-labeled CCPM, which 
had longer blood half life than annexin A5-CCPM, displayed only 2.81 %ID/g in 
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the treated tumors (Fig. 14B). Taken together, our data support the notion that 
increasing the half-life of annexin A5 improved the level of uptake signal in 
apoptotic tissues and was superior for noninvasive detection of apoptotic cells.  
The introduction of CCPM nanoparticles to annexin A5 also may improve 
uptake of annexin A5 in apoptotic tissues through multivalent effect. The overall 
strength of nanoparticle binding to target cells depends on both the affinity of the 
ligand-target interaction and the number of targeting ligands present on the 
nanoparticle surface. Nanoparticles containing multiple targeting ligands can 
provide multivalent binding to cell surface receptors (148). Multivalent effect has 
advantages over monovalency for binding interactions and can increase the 
avidity of interaction of ligands to their target receptor. Using multivalent 
targeting systems, including dimers, tetramers, and multimers, has been 
reported as a successful strategy for enhancing the avidity and/or biological 
functions of peptides, proteins, and antibodies (149-153). This approach is 
particularly useful for ligands that have a weak affinity to their target receptors in 
their monomer form. For example, trastuzumab, an engineered antibody for 
Her2+ breast cancer therapy, was increased in potency up to 25 times through 
conjugation to liposomes (154). In our study, each annexin A5-CCPM 
nanoparticle contained approximately 40 annexin A5 molecules on the surface. 
Thus, the repertoire of annexin A5 was greatly expanded due to multiple, 
simultaneous interactions between the surface of the nanoparticle and the 
surface of the apoptotic cell. The in vitro studies of binding to apoptotic cells 
showed that 111In-labeled annexin A5-CCPM displayed higher detection 
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sensitivity with radioactivity binding assay than monomeric FITC-annexin A5 with 
flow cytometry assay, possibly as a result of increased binding avidity (Fig. 11). 
Similarly, CCPM nanoparticles conjugated with multiple peptides also showed 
multivalent effect in our previously published study (155). The surface plasmon 
resonance (SPR) sensorgrams of this peptide-conjugated CCPM failed to fit into 
the standard 1:1 or 1:2 binding models, indicating that the binding kinetics 
between receptor and peptide-conjugated CCPM were complex. The complex 
binding profile probably was induced by the multivalent nature of this 
nanoparticle.  (Reprinted with the permission of (155)) 
In addition to prolonged circulation time and multivalent effect, the 
enhanced permeability and retention (EPR) effect of CCPM nanoparticles also 
benefit uptake of this imaging tracer in apoptotic areas, which is a form of 
selective targeted delivery termed as passive targeting. The blood vessels in 
some disease areas (such as tumors, inflammations, and infarcted areas) are 
irregular in shape, dilated, leaky or defective, and the endothelial cells are poorly 
aligned. Also, the perivascular cells and the basement membrane are frequently 
absent in the vascular wall. Therefore, long-circulation colloidal particles can 
slowly accumulate in pathological sites with affected and leaky vasculature, 
which is termed as EPR effect (156-160). It strongly depends on the cutoff size 
of blood vessel wall in disease areas (161, 162). Because the usual size of a 
polymeric micelle is 10-80 nm, this passive manner of delivery without specific 
binding to cellular targets has been demonstrated highly effective for polymeric 
micelles (158). It has been repeatedly shown that polymeric micellar 
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nanocarriers, such as adriamycin better accumulate in targeted disease areas 
than in non-target tissues, thus minimizing the undesired drug toxicity towards 
normal tissue (158, 163). Recently, a number of micellar drugs are in 
development based on this mechanism and the EPR effect is becoming a 
golden standard of drug design. Importantly, the EPR effect is a molecular 
weight-dependent phenomenon and functions for molecules or particles larger 
than 60 kDa, which is the threshold of renal clearance. It does not apply to low-
molecular-weight drugs like annexin A5 (160). Therefore, annexin A5 was 
conjugated to CCPM in this study, which also acted as a secondary uptake 
mechanism following EPR-based primary accumulation for better targeting. 
Annexin A5 derivatives labeled with fluorescent dyes for optical imaging 
or radioisotopes for nuclear imaging have been reported for detection of 
apoptosis in preclinical and clinical studies, respectively (14, 15, 22, 23, 78, 80-
84, 86, 102, 164). However, it is highly desirable that an imaging probe 
combining a radioisotope and a near-infrared fluorescent dye be available for 
dual nuclear and optical imaging (165). Nuclear imaging (e.g. PET/CT, 
SPECT/CT), an established clinical imaging modality, offers excellent sensitivity 
and covers the whole body. However, nuclear imaging techniques are limited by 
high cost, radiation exposure and relatively poor spatial resolution. Optical 
imaging techniques have the potential to offer real-time, high-resolution images 
of tissues as long as they are accessible with near-infrared light. Such real-time 
imaging techniques particularly play an important role when studying organs in 
motion, like the beating heart. Moreover, real-time imaging of spontaneous or 
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therapy-induced apoptosis could facilitate and speed up clinical decision. 
Furthermore, the fluorescent signal from the imaging probes permits ex vivo 
analysis of excised tissues and validation of its binding to the molecular targets 
in vivo. Since no imaging modality is perfect, the combination of 2 or more 
imaging techniques can therefore offer synergistic advantages over 1 modality 
alone in providing valuable diagnostic information. To date, several nanoparticle-
based multimodal imaging probes have been developed and applied for 
multimodality functional imaging in living animals (166, 167). These multimodal 
imaging systems have shown great promise in preclinical drug development and 
biomedical research. In this study, Cy-7 dye was entrapped in the core of CCPM 
and radioisotope chelator DTPA was conjugated on the surface of CCPM. Each 
micellar nanoparticle was loaded with multiple Cy7 dye molecules and 111In ions, 
providing a huge boost in signal intensity. As shown in both nuclear and optical 
imaging, 111In-labeled annexin A5-CCPM potentially can be used to locate 
apoptosis by whole-body nuclear and optical imaging. Histologically, 111In-
labeled annexin A5-CCPM revealed apoptotic areas in whole-body scanning 
consistent with autoradiographic and fluorescent findings of tumor sections. 
(Reprinted with the permission of (155)) 
Apoptosis occurs during the normal development and continues 
throughout the whole life. Abnormal apoptosis, especially too much apoptosis, 
can lead to disorders of normal tissues, such as myocardial diseases, 
neurodegenerative diseases, autoimmune diseases, and rejection of 
transplanted organs (liver, heart, lung, kidney) (1, 20-28). Therefore, imaging 
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apoptosis has broader applications other than the monitoring of drug-induced 
tumor apoptosis (168). It is necessary to demonstrate that apoptosis in all types 
of tissues can be visualized by our imaging tracer. In this study, our data showed 
that 111In-labeled annexin A5-CCPM had a great potential for imaging apoptosis 
not only in 4 different tumor apoptosis models, also in hepatic apoptosis and 
inflammation models. In 2 tumor apoptosis models, We observed that 111In-
labeled annexin A5-CCPM preferentially localized at the regions of splenic and 
intramedullary apoptotic injury induced by intraperitoneal injection of 
cyclophosphamide  (Figs. 14A and 21) - a finding that is consistent with the 
previous reports (83, 144). In addition, recent studies suggest that localization of 
annexin A5 does not appear to be entirely specific for apoptosis. Expression of 
PS also occurs with nonlethal cell injury prior to the irreversible changes such as 
DNA breakdown (169, 170). Early identifying expression of PS in injured cells 
may be helpful to defining tissues at risk of cell death and applying therapeutic 
recovery. Annexin A5 is also able to binds to necrotic cells, because of exposure 
of PS located in the inner leaflet of the highly permeable cell membrane of 
necrotic cells (99).  
Since inflammation is associated with a host of diseases, detection of 
inflammation is critical to diagnosis and treatment (171-176). The possibility of 
diagnosing inflammatory processes in the early stage may allow for prevention 
of diseases and early therapeutic intervention. Several Imaging techniques have 
been developed for diagnosis of inflammation, such as ultrasound, CT, MRI, 
PET, and SPECT. Nuclear medicine imaging procedures play an important role 
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in the assessment of inflammatory diseases. Currently, only a few agents are 
used for imaging inflammation in clinic, such as 18F-FDG, 99mTc-labeled 
bisphosphonates, 99mTc or 111In-labeled white blood cells, and radio-labeled 
protein (IgG, albumin). The accumulation of these agents in the site of 
inflammation is generally based on two different mechanisms (177). One is 
specific uptake by inflammatory tissue as a result of increased activities or 
specific cells associated with inflammation, such as 18F-FDG and 99mTc-labeled 
bisphosphonates. The other is unspecific accumulation in inflammatory sites 
because of enhanced vascular permeability. We hypothesize that the 
combination of these two mechanisms might make imaging more sensitive and 
specific. It has been reported that radio-labeled annexin A5 can be used to 
identify macrophages in the site of inflammation in vivo. In our study, CCPM 
nanoparticles displayed higher uptake in inflammatory muscle than in healthy 
muscle (Fig. 28), probably because of enhanced permeability of blood vessels. 
Our design takes advantages of these two mechanisms to increase the uptake 
of this nano-tracer in the site of inflammation and thus improve sensitivity of 
diagnosis.  
In ex vivo studies, apoptotic cells in tissue sections are generally detected 
using transmission electron microscopy (TEM) or microscopy incorporated with 
immunostaining such as H&E and TUNEL (9). Among these assays, TEM is 
considered a golden standard to confirm apoptosis, because of irrefutable 
categorization of an apoptotic cell containing certain ultrastructural 
morphological characteristics (9, 34). However, because the morphological 
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changes generally occur in the later phase of apoptosis, apoptotic cells in the 
early phase will not be detected with these methods. Additionally, TEM is high 
cost, time expenditure, and only allows visualization of a small region at a time. 
Similarly, H&E assay is also based on the morphological changes of apoptotic 
cells. However, these changes rapidly occur in the later phase of apoptosis and 
the fragments are quickly phagocytized so that considerable apoptosis may 
occur in some tissues before it is histologically apparent and cells are in early 
phase of apoptosis will not be detected (9). Due to the ability to detect DNA 
degradation that occurs in a later phase of apoptosis, TUNEL is not suitable for 
cells in the early phase of apoptosis, neither (9, 35). Taken together, regarding 
the mechanisms of these three assays mentioned above, their main 
disadvantage is limitation to the early phase of apoptosis. Therefore, it is very 
desirable to develop a non-invasive imaging tracer that can early and accurately 
detect occurance of apoptosis. This imaging tracer needs to be specifically 
designed on events that occur in the early phase of apoptosis. Externalized PS 
on the outer plasma membrane of apoptotic cells in the early phase of apoptosis 
is considered an optimal marker, which allows for early detection apoptosis via 
annexin A5 (41-44). This assay is sensitive (can detect a single apoptotic cell), 
fast, inexpensive and easy-to-use (9). Thus, we developed annexin A5-
functionalized tracer for imaging apoptosis in this study. Immunohistochemical 
analysis demonstrated a high correlation between localization of 111In-labeled 
annexin A5-CCPM with sites of apoptosis as confirmed by staining with TUNEL, 
H&E and anti-caspase 3 antibody. To sum up, 111In-labeled annexin A5-CCPM 
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has a great potential to early capture occurrence of apoptosis instead of 
conventional histological methods, which is critical and can result in improved 
patient outcomes.  
Though this 111In-labeled annexin A5-CCPM showed a great potential in 
the application of imaging apoptosis in mice, there is still a long way to go if we 
translate it into clinic. It is necessary to perform further studies to investigate it, 
including toxicity, stability, clearance, and efficacy. First, toxicity is considered 
one of the most important properties in the development of new medicines.  
There are thousands of medicines that can’t get the approval from FDA because 
of high toxicity. Therefore, a series of toxicity studies are supposed to be 
conducted in the near future. Secondly, there are many evidences that core-
cross-linked polymeric micelles are relatively stable, especially when they are 
coated with PEG shells. Both autoradiography and optical imaging of tumor 
sections demonstrated that radioactivity signal co-localized with fluorescence 
signal, indicating that CCPM was stable at 48 h post-injection in vivo. However, 
the long-term stability still needs to be elucidated. In addition to toxicity and 
stability, clearance also needs to be considered. It is well known that size of 
nanomedicines generally ranges from 10nm to 1000nm, which is over the 
threshold of renal clearance. Most of nanomedicines are hardly excreted through 
kidney, resulting in accumulation in the bodies for a long period. Therefore, it is 
highly desired to develop degradable nanomedicines for future clinical 
application. In the past few years, a variety of degradable nanomedicines have 
been reported and showed a great potential in drug delivery. Our group is also 
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working on that area. Now we have synthesized the second generation of CCPM 
and made it easily degradable in human body. Our studies demonstrated that 
the second generation of CCPM still kept advantages of first generation. In the 
future, we will conjugate targeting ligands like annexin A5 to new CCPM for 
imaging apoptosis.  
To the end, we envision the following clinical scenario: A patient with a 
suspected abnormal apoptosis lesion will be intravenously administered with a 
single dose of our imaging tracer dual-labeled with radionuclide and optical 
fluorophore. Initially the localization of abnormal apoptotic areas will be 
visualized by whole-body nuclear scanning (SPECT/CT). Subsequently, the 
optical imaging guidance will be applied during surgery procedure to accurately 
remove the abnormal mass. In the meantime, the optical imaging guided 
biopsies could be performed which will be aided by real-time fiber optical 
confocal microscopy imaging “from the tip of the needle” to minimize the false-
negative biopsies.  
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CONCLUSIONS 
 
In this study, we evaluated the potential application of 111In-labeled 
annexin A5-conjugated polymeric micelles for multimodal detection of drug-
induced apoptosis. In 6 different apoptosis models, apoptosis was readily 
visualized with 111In-labeled annexin A5-CCPM using both SPECT and near-
infrared fluorescence imaging. Moreover, annexin A5-CCPM permitted early 
detection of apoptotic cells at the microscopic level by optical imaging for a more 
complimentary diagnosis.  
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